13D Filing: Boyalife Investment Enters Into Agreement With Cesca Therapeutics Inc. (KOOL)

Item 1. Security and Issuer

This Schedule 13D
(this “13D”) is filed with respect to the Common Stock, par value $0.001 per share (the “Shares”),
of Cesca Therapeutics Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s
principal executive offices is 2711 Citrus Road, Rancho Cordova, CA 95742.

Item 2. Identity and Background

Below is information regarding the persons
set forth below (together, the “Reporting

(a) (b) (c)
and (f)

Name	Business Address	Principal Business	Jurisdiction of Formation
Boyalife Investment Inc. (“Boyalife USA”)	c/o Boyalife Group, Ltd. 800 Jiefang Road East Wuxi City, China 214002	Pharmaceutical and Healthcare	USA
Boyalife (Hong Kong) Ltd. (“Boyalife Hong Kong”)	c/o Boyalife Group, Ltd. 800 Jiefang Road East Wuxi City, China 214002	Pharmaceutical and Healthcare	China

(d) Neither of the
Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors).

(e) Neither of the
Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is not subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to
such laws.

The Reporting Persons may be deemed to be
a member of a “group,” within the meaning of Section 13(d)(3) of the Act.

Item 3. Source and Amount of funds or Other Consideration

Pursuant to the transaction
described below, Boyalife USA has acquired 14,705,882 Shares and warrants to purchase 11,764,706 Shares. Boyalife USA has also
acquired a debenture that is convertible upon the occurrence of certain specified events, into 122,058,824 Shares; however such
Shares have not been included in the beneficial ownership of Boyalife USA reported in this Schedule 13D because such Shares are
not acquirable within 60 days of February 13, 2016. Pursuant to the transaction described below, Boyalife Hong Kong has acquired
warrants to purchase 58,823,529 Shares. All funds used by Boyalife USA and Boyalife Hong Kong to acquire such securities came from
cash reserve of respective business entity.